e-learning
resources
Amsterdam 2011
Sunday, 25.09.2011
Biomarkers and outcomes of community-acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Biomarkers in severe community-acquired pneumonia (SCAP) prognosis, complications and outcomes
O. Omelyanenko, A. Makarevich, E. Amelchenko, T. Rybina (Minsk, Belarus)
Source:
Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Session:
Biomarkers and outcomes of community-acquired pneumonia
Session type:
Poster Discussion
Number:
1471
Disease area:
Respiratory critical care, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Omelyanenko, A. Makarevich, E. Amelchenko, T. Rybina (Minsk, Belarus). Biomarkers in severe community-acquired pneumonia (SCAP) prognosis, complications and outcomes. Eur Respir J 2011; 38: Suppl. 55, 1471
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Copeptin application in severe community-acquired pneumonia (SCAP) severity assessment and outcomes
Source: Annual Congress 2012 - Respiratory infections: a clinical point of view
Year: 2012
Procalcitonin and D-dimer to predict prognosis and clinical outcomes in severe community-acquired pneumonia (SCAP) patients
Source: Annual Congress 2012 - Respiratory infections: a clinical point of view
Year: 2012
Thyroid hormones implication in severe community-acquired pneumonia (SCAP): Relationship with survival, outcomes and clinical complications
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Prediction of complications development and lethal outcome in patients with community-acquired pneumonia
Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura
Year: 2011
Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2007; 30: Suppl. 51, 42s
Year: 2007
Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections
Year: 2009
Biomarkers as complication predictors in community-acquired pneumonia
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Incidence, risk factors and outcomes of cardiovascular events in hospitalized patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Complications of respiratory infections: impact of comorbidities and infections caused by Aspergillus
Year: 2009
Management-based risk prediction in community-acquired pneumonia by scores and biomarkers
Source: Eur Respir J 2013; 41: 974-984
Year: 2013
Admission hypoglycaemia is associated with adverse outcome in community-acquired pneumonia
Source: Eur Respir J 2009; 34: 932-939
Year: 2009
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009
The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia
Source: Eur Respir J 2009; 33: 142-147
Year: 2009
Biomarkers and severity in community-acquired pneumonia (CAP)
Source: Annual Congress 2012 - Prognostic indices in respiratory infections
Year: 2012
Risk factors for early onset severe community-acquired pneumonia complications
Source: International Congress 2018 – Pleural diseases and pneumonia: what's new ?
Year: 2018
Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients
Source: International Congress 2015 – Immunodepression and severe pneumonia
Year: 2015
Thrombocytosis is a marker of poor outcome in community-acquired pneumonia
Source: Annual Congress 2012 - Respiratory infections: prognosis and outcome
Year: 2012
Biomarkers for the prognostic assessment and disease severity evaluation in community-acquired pneumonia (CAP)
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010
Clinical factors associated with delayed diagnosis in hospitalized community-acquired pneumonia (CAP). Impact on the outcome
Source: Annual Congress 2010 - Risk factors and outcomes in community-acquired pneumonia
Year: 2010
Role of procalcitonin in predicting severity and in-hospital mortality in patients with community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016
Community-acquired pneumonia in the elderly
Source: Eur Respir Mon; 2009: 43: 111–132
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept